X CONGRESSO DA ABN-RJ / ANERJ – RECONECTANEURO – 2023
Clique no botão abaixo para ter acesso as fotos do X Congresso da ABN-RJ / ANERJ – RECONECTANEURO – 2023. Veja as Fotos...
Clique no botão abaixo para ter acesso as fotos do X Congresso da ABN-RJ / ANERJ – RECONECTANEURO – 2023. Veja as Fotos...
O Projeto de Pesquisa intitulado: “Estudo observacional do uso compassivo do extrato de cannabis associado à farmacoterapia da doença de Parkinson” foi aprovado pelo Comitê de Ética em Pesquisa do IESC/UFRJ. Trata-se de um grande avanço no nosso meio acadêmico. Os grupos da Faculdade de......
Medidas de prevenção para pacientes com Coronavírus: orientação para pacientes, familiares e cuidadores. • Higienização das mãos com água e sabão: o procedimento deve durar 20 segundos e incluir palma, dorso, unhas e regiões entre os dedos. • Álcool em gel a 70% pode ser......
[ABN-RJ] Desafios No Tratamento Da Epilepsia No Sistema Público...
Essa reunião contou com a presença do Dr Giuseppe Didato Neurologista da Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta falando de sua experiência na Itália...
Essa reunião contou com discussão dos centros de referência em Epilepsia do RJ sobre a situação do acompanhamento dos pacientes com epilepsia durante a pandemia e os cuidados necessários para esses pacientes....
Guillain–Barré syndrome (GBS) and its variant, Miller Fisher syndrome (MFS), exist as several clinical subtypes with different neurological features and presentations. Although the typical clinical features of GBS and MFS are well recognized, current classification systems do not comprehensively describe the full spectrum of either syndrome.
In this Perspectives article, GBS and MFS are classified on the basis of current understanding of the common pathophysiological profiles of each disease phenotype. GBS is subclassified into classic and localized forms (for example, pharyngeal–cervical–brachial weakness and bifacial weakness with paraesthesias), and MFS is divided into incomplete (for example, acute ophthalmoparesis, acute ataxic neuropathy) and CNS subtypes (Bickerstaff brainstem encephalitis).
Diagnostic criteria based on clinical characteristics are suggested for each condition. We believe this approach to be more inclusive than existing systems, and argue that it could facilitate early clinical diagnosis and initiation of appropriate immunotherapy.
Guillain–Barré syndrome (GBS) and its variant, Miller Fisher syndrome (MFS), exist as several clinical subtypes with different neurological features and presentations. Although the typical clinical features of GBS and MFS are well recognized, current classification systems do not comprehensively describe the full spectrum of either syndrome.
In this Perspectives article, GBS and MFS are classified on the basis of current understanding of the common pathophysiological profiles of each disease phenotype. GBS is subclassified into classic and localized forms (for example, pharyngeal–cervical–brachial weakness and bifacial weakness with paraesthesias), and MFS is divided into incomplete (for example, acute ophthalmoparesis, acute ataxic neuropathy) and CNS subtypes (Bickerstaff brainstem encephalitis).
Diagnostic criteria based on clinical characteristics are suggested for each condition. We believe this approach to be more inclusive than existing systems, and argue that it could facilitate early clinical diagnosis and initiation of appropriate immunotherapy.